Ahmed Taranissi
Psychiatry · Mexico, MONPI 1215978689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,893 of the $343,244 with a category attached, or 78.3%. 28 manufacturers reported payments, led by Alkermes, Inc. at 29.8% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,716 payments — averaging $200.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$102K
- Neurocrine Biosciences, Inc.$97K
- AbbVie$59K
- Axsome Therapeutics, Inc.$30K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$23K
- Sunovion Pharmaceuticals Inc.$13K
- plus $18K from 22 others
What the payments were for
- Consulting fees$37,57611%
- Speaking & faculty fees$268,89378%
- Travel & lodging$9,9033%
- Food & beverage$26,3768%
- Education$4970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 230 | $102,296 |
| Neurocrine Biosciences, Inc. | 275 | $97,151 |
| AbbVie(2 entities) | 175 | $58,989 |
| Axsome Therapeutics, Inc. | 65 | $30,473 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 180 | $22,591 |
| Sunovion Pharmaceuticals Inc. | 105 | $13,308 |
| Otsuka America Pharmaceutical, Inc. | 183 | $10,792 |
| Teva Pharmaceuticals USA, Inc. | 105 | $1,585 |
| Johnson & Johnson | 71 | $1,285 |
| Supernus Pharmaceuticals, Inc. | 100 | $937 |
| Indivior Inc. | 37 | $524 |
| Lundbeck LLC | 29 | $494 |
| Corium, LLC | 27 | $427 |
| Jazz Pharmaceuticals Inc. | 30 | $415 |
| Vanda Pharmaceuticals Inc. | 23 | $378 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $337 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $329 |
| Ironshore Pharmaceuticals Inc. | 10 | $224 |
| E.r. Squibb & Sons, L.L.C. | 12 | $218 |
| Noven Therapeutics, LLC | 13 | $200 |
| Biohaven Pharmaceuticals, Inc. | 6 | $135 |
| Shire North American Group Inc | 3 | $45 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Validus Pharmaceuticals LLC | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Noven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$199,759
- LYBALVI$197,924
- INGREZZA$93,393
- VRAYLAR$56,173
- ARISTADA INITIO$49,940
- Auvelity$29,843
- CAPLYTA$20,354
- LATUDA$12,002
- ABILIFY MAINTENA$8,284
- REJOYN$130
- INVEGA SUSTENNA$118
- SUNOSI$107
- REXULTI$104
- Azstarys$104
- ABILIFY ASIMTUFII$104
- QELBREE$103
- NURTEC ODT$101
How this compares
$343,244 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 149 | $456,794 |
| IngrezzaValbenazine Tosylate | 47 | $387,576 |
| AustedoDeutetrabenazine | 48 | $296,365 |
| AristadaAripiprazole Lauroxil | 89 | $291,091 |
| VraylarCariprazine Hcl | 167 | $244,340 |
| Invega TrinzaPaliperidone Palmitate | 17 | $170,579 |
| Abilify MaintenaAripiprazole | 59 | $165,450 |
| PerserisRisperidone | 29 | $85,835 |
| CaplytaLumateperone Tosylate | 52 | $84,997 |
| RexultiBrexpiprazole | 54 | $79,215 |
| TrintellixVortioxetine Hydrobromide | 138 | $71,244 |
| SpravatoEsketamine Hcl | 50 | $45,805 |
| Risperdal ConstaRisperidone Microspheres | 19 | $32,648 |
| Paliperidone ErPaliperidone | 121 | $29,129 |
| VyvanseLisdexamfetamine Dimesylate | 58 | $21,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato, Risperdal Consta | $1,285 | $705,825235 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $97,151 | $387,57647 claims |
| Alkermes, Inc.Aristada, Lybalvi | $102,296 | $309,911101 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,585 | $296,36548 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $10,792 | $244,665113 claims |
| AbbVieVraylar | $58,989 | $244,340167 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $329 | $92,852196 claims |
| Indivior Inc.Perseris | $524 | $85,83529 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $22,591 | $84,99752 claims |
| Axsome Therapeutics, Inc.Sunosi, Auvelity | $30,473 | $21,60028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Mexico
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ravdeep KhanujaPoplar Bluff$310K
- Christopher LoyndSaint Louis$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.